No­var­tis on­col­o­gy vet Ste­fan Scher­er joins biotech mi­gra­tion to head clin­i­cal work, CAR-T part­ner­ship at Cel­lec­tis

Cel­lec­tis $CLLS has been busy since Al­lo­gene Ther­a­peu­tics launched in April with a Pfiz­er deal that made them overnight part­ners, rais­ing $164 mil­lion to hus­tle its off-the-shelf CAR-T ther­a­pies along the clin­ic. And it’s now hired a No­var­tis vet­er­an to bol­ster that ac­cel­er­at­ed time­line.

Ste­fan Scher­er’s of­fi­cial ti­tle will be se­nior vice pres­i­dent clin­i­cal de­vel­op­ment and deputy chief med­ical of­fi­cer, re­port­ing to CMO and R&D chief Stéphane De­pil from the French biotech’s New York of­fice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER